Financial Firm Increases Stake in Onconetix

Major shareholder Financial LP HRT buys additional 92,554 shares of the biotech company's stock.

Apr. 18, 2026 at 10:52am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, heavily textured financial machinery and equipment, representing the unseen infrastructure and institutional power behind stock market transactions.A major investor's increased stake in a biotech firm signals confidence in the company's future prospects despite recent stock price declines.Cincinnati Today

Onconetix, Inc., a Cincinnati-based biotechnology company focused on men's health and oncology solutions, saw a major shareholder increase its stake in the company. Financial LP HRT, which already owned a significant portion of Onconetix, purchased an additional 92,554 shares in a transaction on April 15, 2026.

Why it matters

This purchase by a major investor signals confidence in Onconetix's future prospects and could indicate the company's products and pipeline are gaining traction in the market. Insider trading activity is closely watched by investors as it can provide insights into a company's outlook.

The details

Financial LP HRT acquired the 92,554 Onconetix shares at an average price of $0.76 per share, for a total transaction value of $70,341.04. This increased the firm's ownership stake in Onconetix to 197,052 shares, valued at approximately $149,759.52. The purchase represented an 88.57% increase in Financial LP HRT's existing position in the company.

  • The stock purchase transaction was completed on April 15, 2026.
  • Onconetix's current 50-day moving average price is $2.86, while the 200-day average is $8.81.

The players

Financial LP HRT

A major shareholder and institutional investor in Onconetix, Inc.

Onconetix, Inc.

A biotechnology company focused on developing solutions for men's health and oncology, headquartered in Cincinnati, Ohio.

Got photos? Submit your photos here. ›

The takeaway

This insider transaction suggests Financial LP HRT sees significant upside potential in Onconetix's product portfolio and future growth prospects, even as the company's stock price has declined from its 52-week high. Investors will likely monitor Onconetix's financial performance and pipeline developments closely in the coming quarters.